Erratum to: Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years’ treatment
© The Author(s). 2016
Received: 6 July 2016
Accepted: 6 July 2016
Published: 12 July 2016
Following the publication of our article “Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years’ treatment” by Kampmann et al.  we have become aware that the dose of agalsidase alfa was not reported.
Eligible patients had a Fabry disease diagnosis confirmed by enzyme assay (males) and/or DNA analysis (males and females), were aged ≥14 years at treatment start, and had received agalsidase alfa (Replagal®; Shire, Lexington, Massachusetts, USA) ERT at a dose of 0.2 mg/kg body weight every other week for approximately 10 years.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.